The use of MCT1 inhibitor AR‐C155858 revealed the potential of this target as a specific anti‐tumour therapy affecting apoptosis and proliferation in tumours, with no adverse effects seen in benign glands. This evidence concerns the gene SLC16A1 and neoplasm.